<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals has submitted an initial disclosure to NSE and BSE clarifying that it does not qualify as a 'Large Corporate' under SEBI's framework as of March 31, 2026. The company cited SEBI Circular dated October 19, 2023 as the reference for this disclosure requirement. The filing includes a negative confirmation stating that specified criteria for Large Corporate classification are not applicable to the company. The annexure shows 'Not applicable' for outstanding borrowing, credit ratings, and fine payment requirements since the company falls outside the LC category.
This filing has no direct impact on shareholders as it confirms Lincoln Pharmaceuticals does not meet Large Corporate thresholds. This is a routine regulatory compliance disclosure confirming the company's smaller corporate status under SEBI guidelines.